CA3181388A1 - Methylthioninium compounds for use in the treatment of hypoxemia - Google Patents

Methylthioninium compounds for use in the treatment of hypoxemia

Info

Publication number
CA3181388A1
CA3181388A1 CA3181388A CA3181388A CA3181388A1 CA 3181388 A1 CA3181388 A1 CA 3181388A1 CA 3181388 A CA3181388 A CA 3181388A CA 3181388 A CA3181388 A CA 3181388A CA 3181388 A1 CA3181388 A1 CA 3181388A1
Authority
CA
Canada
Prior art keywords
subject
acid
hypoxia
containing compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3181388A
Other languages
English (en)
French (fr)
Inventor
Claude Michel Wischik
Mohammad ARASTOO
Michael Philip Mazanetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006659.3A external-priority patent/GB202006659D0/en
Priority claimed from GBGB2016957.9A external-priority patent/GB202016957D0/en
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CA3181388A1 publication Critical patent/CA3181388A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3181388A 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of hypoxemia Pending CA3181388A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2006659.3 2020-05-05
GBGB2006659.3A GB202006659D0 (en) 2020-05-05 2020-05-05 Therapeutic treatments
GB2016957.9 2020-10-26
GBGB2016957.9A GB202016957D0 (en) 2020-10-26 2020-10-26 Beneficial treatment
PCT/EP2021/061485 WO2021224146A1 (en) 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of hypoxemia

Publications (1)

Publication Number Publication Date
CA3181388A1 true CA3181388A1 (en) 2021-11-11

Family

ID=75887990

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3181388A Pending CA3181388A1 (en) 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of hypoxemia

Country Status (12)

Country Link
US (1) US20230158040A1 (https=)
EP (1) EP4146225B1 (https=)
JP (1) JP2023524146A (https=)
KR (1) KR20230012515A (https=)
CN (1) CN115916211A (https=)
AU (1) AU2021268465A1 (https=)
CA (1) CA3181388A1 (https=)
ES (1) ES2992641T3 (https=)
MX (1) MX2022013884A (https=)
PL (1) PL4146225T3 (https=)
TW (1) TWI907424B (https=)
WO (1) WO2021224146A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
US20060264423A1 (en) 2005-05-20 2006-11-23 Bioenvision, Inc. Methylene Blue Therapy of Viral Disease
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) * 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
EP3982974A4 (en) * 2019-06-12 2023-06-21 Achal Narendrakumar Agrawal NOVEL IMPROVED PROCESS FOR THE SYNTHESIS OF DIAMINOPHENOTHIAZINE COMPOUNDS

Also Published As

Publication number Publication date
EP4146225B1 (en) 2024-10-09
TW202200149A (zh) 2022-01-01
BR112022022322A2 (pt) 2022-12-13
ES2992641T3 (en) 2024-12-16
TWI907424B (zh) 2025-12-11
CN115916211A (zh) 2023-04-04
MX2022013884A (es) 2022-11-30
JP2023524146A (ja) 2023-06-08
WO2021224146A1 (en) 2021-11-11
US20230158040A1 (en) 2023-05-25
PL4146225T3 (pl) 2025-03-10
AU2021268465A1 (en) 2022-12-08
EP4146225C0 (en) 2024-10-09
EP4146225A1 (en) 2023-03-15
KR20230012515A (ko) 2023-01-26

Similar Documents

Publication Publication Date Title
Dabholkar et al. Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations
JP2004525080A (ja) 血漿リポタンパク質及び心臓血管疾患の危険因子を減ずるための組成物及び方法
Schuurmans et al. Practical approach to early postoperative management of lung transplant recipients
EP4146225B1 (en) Methylthioninium compounds for use in the treatment of hypoxemia
US20230165875A1 (en) Methylthioninium compounds for use in the treatment of covid-19
CN104519881A (zh) 使用no(一氧化氮)供体诱导动脉生成
HK40088921B (en) Methylthioninium compounds for use in the treatment of hypoxemia
HK40088921A (en) Methylthioninium compounds for use in the treatment of hypoxemia
BR112022022322B1 (pt) Uso de compostos de metiltionínio para preparação de medicamento oral para tratamento de hipoxemia
SAKAI et al. Lidocaine ingestion
US20230165876A1 (en) Methylthioninium compounds for use in the treatment of covid-19
US20250222005A1 (en) Methylene blue containing compounds for the treatment of methaemoglobinaemia
CN119837862A (zh) 玛沃谷兰在减少酒精使用或在预防复用酒精中的用途
US20140066502A1 (en) Use of Stabilized Granules Containing Glyceryl Trinitrate for Arteriogenesis
Iliev et al. Acute poisoning with dapsone and olanzapine: severe methemoglobinemia and coma with a favourable outcome
WO2021224914A1 (en) Treatment of viral infection, disease or disorder using a selective s1r agonist

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250403

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250403

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250423

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250423

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250623

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250623

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250623

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250709